HISTORICAL FACTS: Vrtx - The Untold Story

How Is Vertex Pharmaceuticals' Stock Performance Compared to Other Biotech Stocks?

Vertex Pharmaceuticals has underperformed the Biotech industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart · Sep 2

Are Wall Street Analysts Bullish on Vertex Stock?

Vertex Pharmaceuticals has raced ahead of the market, while analysts continue to give the stock a decidedly optimistic outlook.

Barchart · Aug 20

What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report

Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.

Barchart · Jul 13

Is Vertex Stock Outperforming the Dow?

Despite underperforming the Dow Jones Industrial Average over the past year, Vertex continues to earn moderate bullish support from analysts.

Barchart · Feb 26

Vertex Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Vertex Pharmaceuticals’ stock has lagged behind the broader market over the past year, but analysts remain moderately bullish about its prospects.

Barchart · Feb 17

Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report

Vertex Pharmaceuticals is scheduled to post its fourth-quarter results soon, and analysts project a double-digit earnings growth

Barchart · Jan 13

Vertex's Gene Therapy Works In Children With Blood Disorders

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Saturday presented data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in patients aged 5 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).

Benzinga · Dec 8, 2025

Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings

Vertex Pharmaceuticals’ stock has trailed behind the broader market, but analysts are still taking a moderately bullish stance about its prospects.

Barchart · Nov 18, 2025

Is Vertex Pharmaceuticals Stock Underperforming the S&P 500?

Vertex Pharmaceuticals has lagged the broader S&P 500 Index over the past year, but Wall Street analysts remain moderately optimistic about the company’s long-term prospects.

Barchart · Sep 8, 2025

Do Wall Street Analysts Like Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has significantly underperformed the broader market over the past year, yet analysts remain optimistic about the stock’s prospects.

Barchart · Aug 25, 2025